Saroglitazar Boosts Response Rates in Primary Biliary Cholangitis

(MedPage Today) -- Novel saroglitazar significantly improved biochemical response rates in patients with primary biliary cholangitis (PBC) who had an inadequate response to ursodeoxycholic acid or couldn't tolerate it, according to the EPICS-III...
Source
MedPage Today
Opens original article in a new tab


